Bibliografia
1. Buonadonna g., RobustelliG., Valagussa P., Medicina oncologica ottava edizione 2007
2. Cnossen J.A., et al., Long term survival with metastatic brest cancer (MBC): results of a retrospective, single-centre analysis from 2000-2005. 2008 ASCO Annual Meeting; abstract n. 1128
3. Palmieri S., Vaglica M., Carcinoma mammario metastatico: quali farmaci in seconda linea? Supplemento a International Trends in Oncology – vol. IX – n.3/2005, 30-42
4. Bonneterre J., Nabholtz J. M., et al., Anastrozole is superior to tamoxifen as first line therapy in hormone receptor positive advanced breast carcinoma . Cancer 2001; 92: 2247-2258
5. Nabholtz J. M., et al., Anastrozole is superior to tamoxifen as first line therapy for advanced breast cancer in postmenopusal women:
results of a North American multicenter trial. J Clin Oncol 2000; 18:
3758-3767
6. Paridaens R., Dirix L., et al., First line hormonal treatment (HT) for metastatic breast cancer: a randomized phase III trial of EORTC Breast Group. Proc AMm Soc Clin Oncol 2004; 22 (S1): 515
7. Mouridsen H. et al., Superior efficacy of letrozole versus tamoxifen as first line therapy for postmenopausal women with metastatic breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596-2606
8. Mouridsen H. et al., Phase III study of letrozole versus tamoxifen as first line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;
21: 2101-2109
9. Klijn J. G., Boccardo F., et al., Combined tamoxifen and luteinizing hormone- releasing hormone (LH-RH) agonist versus LH-RH agonist alone in premenopausal advanced breast cancer: a meta- analysisof four randomized trial. J Clin Oncol 2001; 19: 343-353
10. S.Carrick et al., Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane database of systematic reviews 2008; issue n.3
11. A’Hern R. P. A., Smith I. E. et al., Chemotherapy and survival in advanced breast cancer:the inclusion of doxorubicin in Cooper type regimens. Br J Cancer 1993; 67: 801-805
12. Fossati R., Confalonieri C., Torri V., et al.,Cytotoxic and hormonal treatment for metastatc breast cancer: a systematic revie of published randomized trials involving 31.510 women.J Clin Oncol 1998; 16: 3439-3460
13. Gianni L., et al., Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic brest cancer:
high anti-tumor efficacy and cardiac effects in dose-findingand sequence-finding study. J Clin Oncol 1995; 13: 2688-2699
14. Gehl J. Et al., Combineed doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 1996; 7: 687- 693
15. Bellot R., et al., Taxotere does not change the pharmacokinetics profile of doxorubicin and doxorubicinol. Proc Am Soc Clin Oncol1998; 17: 221a
16. Nabhlotz J.M. et al., Docetaxel and doxorubicin compared with cyclophosphamide and doxorubicin as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003; 21: 968-975
17. Mackey J. R. et al., Final results of the phase III randomizes trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C)
to FAC as first-line chemotherapy (CT) for patients with metastatic breast cancer(MBC). Proc Am Soc Clin Oncol 2002; 21 (abstr. 137)
18. Bonneterre J., Dierras V. et al., Phase II multicentre randomized study of docetaxel plus epirubicin versus 5-fluororucil plus epirubicin and cyclophosphamide in metastatic breast cancer.
British J Cancer 2004; 91: 1466-1471
19. Piccard Gebhart M. J. et al., Taxanes alone or in combination with anthracyclines as first-line therapy of patient with metastatic breast cancer. J Clin Oncol 2008;26: 1980-1986
20. Conte P.F., Guarnieri V., et al., Concomitant versus sequential administration of epirubicin and paclitaxel as first line therapy in metastatic breast carcinoma. Cancer 2004; 101: 704-712
21. Slamon D. J :, Leyland-Jones B. Use of chemotherapy plus monoclonal antybody against HER-2 for metastatic breast cancer that overexpress HER-2. N Eng J Med 2001 ; 344 : 783-792
22. Kardinal C.G. et al., Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. A subset analysis of CALGB study 8081.
Cancer 1988; 61: 415-419
23. Venturini M, Bruzzi P. Et al., Effect of adjuvant chemotherapy with or wiyhout anhracyclines on the activity and efficacy of first line cyclophosphamide, epidoxorubicin and fluorouracil in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 764- 773
24. Pierga J.Y:, et al., Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first line doxorubicin containing chemotherapy. Cancer 2001; 91: 1079-1089
25. Gennari A. Et al., Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy.
Br J Cancer 2004; 90: 962-967
26. Bonneterre J., Besljia S., et al., Second consensus on medialtreatment of metastatic breast cancer. Ann Oncol 2007; 18:
215-225
27. Vander Heide R. S. et al., Molecular basis of anthracycline-induced cardiotoxicity. Heart metab 2007; 35:1-4
28. Billingham M. E. et al., Anthracycline cardiomiopathy monitored by morphologic changes. Cancer Treat Rep 1978; 62: 865-872
29. Swain S. M. et al., Congestive heart failure in patients treated with doxorubicin. Cancer 2003; 97: 2869-2879
30. Safra T. Cardiac safety of liposomal anthracyclines. The oncologist 2003; 8(suppl 2):17-24
31. Marty M., Monnier A., et al., Multicenter randomized phase III study of tha cardioprotective effect of dexrazoxane in advanced/metastatic breast cancer patients treated with anthracycline based chemotherapy. Ann Oncol Genn 2006: 1-9
32. Ryberg et al., Epirubicin cardiotoxicity: an analysis of 469 patients with advanced breast cancer. J Clin Oncol 1985; 3: 818-826
33. Launchbury AP, Habboubi N, et al. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity.
Cancer Treat. Rev. 1993; 19: 197-228
34. Coukell AJ Faulds. Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer. Drugs 1997; 53:453-82
35. Jensen B.V. et al., Functional monitoring of anthracycline cardiotoxicity : a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002; 13: 699-709
36. Lorusso V., Manzione L. et al., Role of liposomal anthracyclines in breast cancer. Ann Oncol 2007 ; 18 (suppl 6) : 70-73
37. Rivera E., Liposomal anthracyclines in metastatic breast cancer : clinical update. The Oncologist 2003 ; 8 (suppl 2):3-9
38. Gordon A. N., et al., Recurrent epithelial ovarian carcinoma:a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19:3312-3322
39. Gabizon A. et al., Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumors. Drugs 1997;54:15-21
40. O’Brien M. E. R., Wigler N., et al., Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (Caelix®/Doxil®) versus conventional doxorubicin for first line treatment of metastatic breast cancer. Ann Oncol 2004 ; 15: 440, 449
41. Valero V. et al., Phase II trial of Liposome-Encapsulated Doxorubicin, Cyclophosphamide, and Fluorouracil as first-line therapy in patients with Metastatic Breast Cancer. J Clin Oncol 1999; 17: 1425-1434
42. Batist G, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicentre trial of metastatic breast cancer. J Clin Oncol 2001; 19: 1444-54
43. Harris L, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first line therapy for metastatic breast carcinoma. Cancer 2002; 94: 25- 36
44. Alexopoulos A., e al., Phase II study of pegylated liposomal doxorubicin (Caelix®) and docetaxel as first-line treatment in metastatic breast cancer. Annals of Oncology 2004; 15:891-895
45. Guastalla J. P., Largillier R., et al., Docetaxel (Do) and liposomal pegylated doxorubicin in metastatic breast cancer (MBC) patients : tha French GINECO group experience. J Clin Oncol 2006; 24 (suppl.20)
46. Morabito A. et al,. Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer. Brest Canc Res Treat 2004; 86: 249-257
47. Rosati M.S., Raimondi S. et al., WALT trial (phase I/II): weekly non pegylated liposomal anthracycline and taxane combination in first line breast cancer chemotherapy. J Clin Oncol ASCO Meeting Abstracts 2008 26: 1097
48. Verweij J. et al., Paclitaxel (Taxol) and docetaxel (Taxotere) : not simply two of kind. Ann Oncol 1994 ; 5 : 495-505
49. Lavelle F., Bissery M.C., et al., Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 1995 ; 22 : 3-16
50. Bissery M.C., NohynekG., et al., Doceyaxel (Taxotere) : a review of preclinical and clinical experience . Drugs 1995; 6: 339-368
51. Jones S.E. et al., Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005 ; 24:
5542-5549
52. Valero V., Jones S.E. et al., A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998 ; 16 : 3362-3368
53. Rivera E. et al., Phase III study of docetaxel weekly (DW) versus every 3 weeks (D) in patients with metastatic breast cancer: final result. J Clin Oncol 2006; 24: 574
54. Martin M. et al., Multicentre randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish breast cancer research group (GEICAM-9903) phase III study. J Clin Oncol 2004; 22(13): 2587-2593
